Citations

Clear

4847 citation(s) found for "Yu, Eric".

Modeling post‐translational modifications and cancer‐associated mutations that impact the heterochromatin protein 1α‐importin α heterodimers
Zimmermann, Michael T. , Williams, Monique M., Klee, Eric W. , Lomberk, Gwen , Urrutia, Raúl , Lomberk, Gwen L , Zimmermann, Michael T , Urrutia, Raul

Mayo Clinic

Proteins: Structure, Function, and Bioinformatics | June 1, 2019 | Volume: 87 | Issue: 11 | Pages: 904-916

10.1002/prot.25752 | PMID 31152607 Get It

AbstractHeterochromatin protein 1α (HP1α) is a protein that mediates cancer‐associated processes in the cell nucleus. Proteomic experiments, reported here, demonstrate that HP1α complexes with importin α (IMPα), a protein necessary for its nuclear transport. This data is congruent with Simple Linear Motif (SLiM) analyses that identify an IMPα‐binding motif within the linker that joins the two globular domains of this protein. Using molecular modeling and dynamics simulations, we develop a model of the IMPα‐HP1α complex and investigate the impact of phosphorylation and genomic variants on their interaction. We demonstrate that phosphorylation of the HP1α linker likely regulates its association with IMPα, which has implications for HP1α access to the nucleus, where it functions. Cancer‐associated genomic variants do not abolish the interaction of HP1α but instead lead to rearrangements where the variant proteins maintain interaction with IMPα, but with less specificity. Combined, this new mechanistic insight bears biochemical, cell biological, and biomedical relevance.
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease
Liu, Huan , He, Jin , Koh, Su Pin , Zhong, Yuping , Liu, Zhiqiang , Wang, Zhi‐Qiang , Zhang, Yujin , Li, Zongwei , Tam, Bjorn T. , Xiao, Min , Starbuck, Michael W., Navone, Nora M. , Davis, R. Eric , Tong, Qiang , Bergsagel, P. Leif , Yi, Qing , Orlowski, Robert Z. , Yang, Jing , Bergsagel, P. Leif , Xiao, Min , Amini, Behrang , Navone, Nora M , Davis, Richard E , Tong, Qiang , Yi, Qing , Gagel, Robert F. , Yang, Jing , Orlowski, Robert Z. , Lin, Pei , Young, Ken H. , Lee, Hans C. , Hou, Jian , Liu, Zhiqiang

Mayo Clinic

Science Translational Medicine | May 29, 2019 | Volume: 11 | Issue: 494 | Pages: No page available

10.1126/scitranslmed.aau9087 | PMID 31142679 Get It

Marrow adipocytes reprogrammed by myeloma cells induce bone lesions.
Platelet-Rich Emboli in Cerebral Large Vessel Occlusion Are Associated With a Large Artery Atherosclerosis Source
Wang, Shunli , Douglas, Andrew , Kadirvel, Ramanathan , Thacker, Ike, Gounis, Matthew J. , Chueh, Ju-Yu , Puri, Ajit S , Sauvageau, Eric , Aghaebrahim, Amin, Kvamme, Peter , Kallmes, David F. , Doyle, Karen , Brinjikji, Waleed , Fitzgerald, Seán , Dai, Daying , Layton, Kennith F. , Almekhlafi, Mohammed , Demchuk, Andrew M. , Hanel, Ricardó A. , Yoo, Albert J. , Mendes Pereira, Vitor , Kayan, Yasha , Almandoz, Josser E Delgado , Nogueira, Raul G. , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | May 29, 2019 | Volume: 50 | Issue: 7 | Pages: 1907-1910

10.1161/strokeaha.118.024543 | PMID 31138084 Get It

Background and Purpose— Nearly 30% of large vessel occlusion acute ischemic stroke clots are from an unknown source. We assessed histological clot composition in a series of patients with large vessel occlusion and investigated correlations between clot composition and stroke pathogenesis. Methods— As part of the multi-institutional STRIP registry (Stroke Thromboembolism Registry of Imaging and Pathology), consecutive emboli retrieved during mechanical thrombectomy were stained using Martius Scarlett Blue and analyzed using machine learning software. We assessed proportions of red blood cells, fibrin, platelets, and white blood cells. Correlations between clot components and stroke pathogenesis (large artery atherosclerosis, cardioembolism, and stroke of undetermined pathogenesis) were assessed using SPSS22. Results— One hundred five patients were included. The proportion of platelet-rich clots (55.0% versus 21.2%; P =0.005) and percentage of platelet content (22.1±4.2% versus 13.9±14.2%; P =0.03) was significantly higher in the large artery atherosclerosis group compared with the cardioembolic group. The proportion of platelet-rich clots (50.0% versus 21.2%; P =0.024) was also significantly higher in the cryptogenic group compared with cardioembolic cases. Large artery atherosclerosis and cryptogenic cases had a similar proportion of platelet-rich clots (55.0% versus 50.0%; P =0.636). There was no significant difference between stroke pathogenesis and the other major clot components. Conclusions— High platelet content of emboli is associated with a large artery atherosclerosis etiology of large vessel occlusion.
Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects
Hatsukami, Dorothy K. , Luo, Xianghua , Heskin, Alisa K., Tang, Mei Kuen , Carmella, Steven G. , Jensen, Joni , Robinson, Jason D. , Vandrey, Ryan G. , Drobes, David J., Strasser, Andrew A. , Al’Absi, Mustafa , Leischow, Scott J. , Ikuemonisan, Joshua , Benowitz, Neal L. , Cinciripini, Paul M , Benowitz, Neal L , Koopmeiners, Joseph Stephen , Donny, Eric C. , Hecht, Stephen S.

Mayo Clinic

Addiction | May 29, 2019 | Volume: 114 | Issue: 10 | Pages: 1824-1833

10.1111/add.14695 | PMID 31140663 Get It

Abstract Aim A previous study showed significantly greater reductions in number of cigarettes smoked and biomarkers of toxicant and carcinogen exposure in smokers assigned to immediate reduction of nicotine in cigarettes to very low levels versus gradually over time or continued smoking of normal nicotine content cigarettes. This study examines the effects of these approaches on selected biomarkers associated with harmful biological effects. Design Three‐arm, randomized controlled trial. Setting Ten United States academic institutional sites. Participants Daily smokers uninterested in quitting smoking with a mean age of 45.1 [standard deviation (SD) = 13.4)] years and smoking 17.1 (SD = 8.5) cigarettes/day; 43.9% (549 of 1250) female; 60.6% (758 of 1250) white ethnicity. Interventions (1) Smoking cigarettes where nicotine content was immediately reduced to very low levels ( n = 503); (2) smoking cigarettes where nicotine content was gradually reduced, with dose changes occurring monthly ( n = 498); and (3) continued smoking with normal nicotine content cigarettes ( n = 249). Measurements Smokers were assessed at baseline while smoking their usual brand cigarettes, and again at 4, 8, 12, 16 and 20 weeks. Outcomes were areas under the concentration time curve (AUC) for the period of study of biomarkers of inflammation, oxidative stress and hematological parameters. Findings No consistent significant differences were observed across groups (Bayes factors showing data to be insensitive), with the only exception being red blood cell size variability, which was observed to be lower in the immediate versus gradual nicotine reduction [mean difference = −0.11; 95% confidence interval (CI) = –0.18, −0.04, P = 0.004] and normal nicotine control groups (mean difference = − 0.15, 95% CI = –0.23, −0.06, P = 0.001). Conclusion It remains unclear whether switching to very low nicotine cigarettes leads to a short‐term reduction in biomarkers of tobacco‐related harm.
Pulmonary Complications of Rheumatoid Arthritis
Farquhar, Hamish , Vassallo, Robert , Edwards, Adrienne L. , Matteson, Eric L. , Vassallo, Robert

Mayo Clinic

Seminars in Respiratory and Critical Care Medicine | May 28, 2019 | Volume: 40 | Issue: 02 | Pages: 194-207

10.1055/s-0039-1683995 | PMID 31137060 Get It

Rheumatoid arthritis (RA) is a common chronic autoimmune disorder that characteristically causes joint inflammation and damage. In addition, many patients develop extraarticular manifestations which may cause significant comorbidity and premature mortality.Some respiratory tract involvement of the upper and lower airways and parenchymal disease features are unique to RA, including cricoarytenoid arthritis and RA pulmonary nodulosis, and others, especially the interstitial parenchymal involvement, occur in many other idiopathic and autoimmune diseases. The pathophysiology of lung disease is not well understood. Rheumatoid lung disease may even predate the onset of joint disease, and could be triggered by chronic airway and alveolar epithelial injury. Chronic systemic inflammation and risk factors such as cigarette smoking, infection, host genetics, and immune dysregulation are contributors. Treatment of the respiratory disease is directed at reducing the systemic inflammation of RA. Less well understood is the management of the interstitial lung disease of RA, for which antifibrotic and immune suppressive agents may be helpful. The management of RA-related lung disease is perhaps the major remaining hurdle in reduction of the disease burden related to extraarticular manifestations of this disease.
The Importance and Challenges of Developing a Pharmacogenetics Test for Hypertension
Snyder, Eric M., Kelley, Eli F. , Sprissler, Ryan , Olson, Thomas P.

Mayo Clinic

Pharmacogenomics | May 28, 2019 | Volume: 20 | Issue: 8 | Pages: 563-566

10.2217/pgs-2019-0056 | PMID 31136254 Get It

Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy.
Roeland, Eric , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Clark-Snow, Rebecca, Wickham, Rita S., Binder, G. , Sebastiani, Silvia , Papademetriou, Eros , Schmerold, Luke, Navari, Rudolph M. , Leblanc, Thomas , Roeland, Eric J , Sebastiani, Silvia, Potluri, Ravi C.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e23108-e23108

10.1200/jco.2019.37.15_suppl.e23108 Get It

e23108 Background: ASCO antiemetic guidelines recommend upfront triple prophylaxis (NK1 receptor antagonist (RA) + 5HT3 RA + dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC). Physicians exhibit high variation in HEC guideline adherence, principally involving inclusion of NK1 RA. Whether adherence is associated with selection of the specific 5HT3 RA agent remains inadequately studied. Methods: In the IBM Explorys electronic health record database, we used procedure and diagnosis codes to identify HEC courses and related nausea/vomiting (NV) from 2012 to 2018. We defined HEC guideline adherence as triple prophylaxis at chemotherapy initiation. We assigned HEC courses for ≥ 7 day cycles of cisplatin or anthracycline + cyclophosphamide (AC), or carboplatin (≥ 14 day cycles as a proxy for AUC ≥ 4) to prescribing oncologists based on encounter frequency. We categorized 5HT3 RA use of each physician treating ≥ 5 HEC courses based on their most commonly used 5HT3 and performed descriptive statistics. Results: Of 12,262 HEC courses, 57% involved physicians having greater use of ondansetron (OND) (mean OND to palonosetron (PALO) ratio of 3.9:1). These courses had lower guideline adherence (due to NK1 RA omission) and higher rates of NV for combined HEC, AC, and carboplatin. NV rates for cisplatin did not vary by 5HT3 agent used. Courses involving physicians with greater PALO use (mean OND:PALO ratio of 0.2:1) had superior adherence and NV rates, despite involving a slightly higher risk population (younger and/or female). Conclusions: According to HEC antiemetic guidelines, NK1 RA use should occur independent of 5HT3 RA agent selection. However, we observed less NK1 RA use where OND was preferred, which may have caused the observed higher rates of NV with OND. Further evaluation should assess whether pharmacy cost minimization is a driver of both OND preference and NK1 omission in HEC. [Table: see text]
Clinical course of patients with cisplatin (CDDP)-associated neuropathy compared to other neurotoxic chemotherapy.
Albany, Costantine , Dockter, Travis , Wolfe, Eric, Pachman, Deirdre R. , Wagner‐Johnston, Nina D. , Lazzara, Kayla Marie, Sego, Lina M., Edwards, Sara I, Snow, C, Hanna, Nasser H. , Einhorn, Lawrence H. , Loprinzi, Charles L. , Costello, Brian A.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e23078-e23078

10.1200/jco.2019.37.15_suppl.e23078 Get It

e23078 Background: There are limited patient (pt) reported outcome data regarding CDDP neurotoxicity. Methods: CDDP-induced peripheral neuropathy was evaluated in pts with testicular cancer planning to receive CDDP (20 mg/m2/d for 5 days) for ≥ 3 cycles. Neurotoxicity was assessed with the EORTC QLQ-CIPN20 tool before each CDDP cycle and every 2-4 months after, out to 18 months. We compared these data to our studies evaluating pts receiving doxorubicin/cyclophosphamide (AC), paclitaxel and oxaliplatin. The total score of the EORTC QLQ-CIPN20, each of the three subscale scores and each individual item was computed following the standard scoring algorithm and converted to a 0-100 scale. Descriptive statistics and graphical plots were utilized. Results: 54 pts receiving CDDP (mean age 33 years) and 18 pts receiving AC were evaluated. Following completion of CDDP, neuropathy symptoms (sensory neuropathy score and numbness/tingling in toes/feet) worsened for about 6 months (consistent with the so-called “coasting phenomena”), similar to what had previously been seen with oxaliplatin (but different than what had been seen with paclitaxel). For CDDP pts, during therapy, numbness and tingling in fingers/hands were more prominent, than the same symptoms in the toes/feet. After therapy was completed, numbness, and tingling became more prominent in toes/feet, but improved in the fingers/hands. After stopping therapy, shooting/burning pain did not worsen in upper or lower extremities. During therapy, CDDP pts had less problems than had previously been seen with oxaliplatin or paclitaxel, maybe because of the younger ages of the CDDP pts. With AC, all of the CIPN-20 sensory neuropathy scores were better than was seen in the pts receiving CDDP and also in pts receiving paclitaxel and oxaliplatin in previous evaluations. Conclusions: CDDP-induced neuropathy is more similar to oxaliplatin-induced neuropathy than paclitaxel-induced neuropathy. AC chemotherapy pts do not have substantial changes in CIPN 20 scores, consistent with the CIPN 20 instrument being a measure of chemotherapy-induced neuropathy, as opposed to more general chemotherapy-induced toxicities. Clinical trial information: NCT02677727.
Reply
Duarte‐García, Alí , Crowson, Cynthia S. , Warrington, Kenneth J. , Matteson, Eric L. , Duarte-García, Alí , Warrington, Kenneth J

Mayo Clinic

Arthritis & Rheumatology | May 28, 2019 | Volume: 71 | Issue: 10 | Pages: 1769-1770

10.1002/art.41000 | PMID 31135097 Get It